European Medicines Agency
Press office

London, 23 July 2009
Doc. Ref. EMEA/412751/2009

PRESS RELEASE
Gendux Molecular Limited withdraws its marketing authorisation application for Contusugene ladenovec Gendux (contusugene ladenovec)

The European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Contususgene ladenovec Gendux (contusugene ladenovec), suspension for injection.

Contusugene ladenovec Gendux was expected to be used for the treatment of squamous cell carcinoma in head and neck cancer.

The application for the marketing authorisation for Contususgene ladenovec Gendux was submitted to the Agency on 2 July 2008. At the time of withdrawal, it was under review by the Agency's Committee for Medicinal Products for Human Use (CHMP).

In its official letter, the company stated that the withdrawal of the application was based on the difficult financial situation of its parent company Introgen Therapeutics, Inc., which prohibits them to fund further activities related to this application.

More information about Contusugene ladenovec Gendux and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency's website shortly.

-- ENDS --

Notes:

1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.
2. This press release, together with other information on the work of the European Medicines Agency, can be found on the Agency's website: www.emea.europa.eu.

Media enquiries only to:
Monika Benstetter
Tel. (44-20) 74 18 84 27, E-mail press@emea.europa.eu